The Clinical and Molecular Profile of Metastatic Gliomas

[26 oct 2025]

> Key findings of the article: "Barthel FP. Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas. Neuro Oncol. 2025 Oct 15:noaf244. doi: 10.1093/neuonc/noaf244. Epub ahead of print. PMID: 41092320." Comparing also with similar article. At the end give me the intere bibliography you used, in Vancouver form.

Here's a summary of the key findings from the article by Barthel FP, along with a comparison to a similar study, and the full bibliography in Vancouver format.

🧠 Key Findings: Barthel FP (2025) – *Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas*

This editorial explores the rare but clinically significant phenomenon of gliomas that metastasize outside the central nervous system (CNS). Key insights include:

- **Rarity and Complexity**: Metastatic gliomas are exceptionally rare, with extracranial spread occurring in less than 2% of cases. Their biology remains poorly understood due to limited sample sizes.
- **Molecular Features**: These tumors often harbor aggressive molecular signatures, including alterations in TP53, EGFR amplification, and CDKN2A/B deletions. Barthel emphasizes the need for deeper genomic profiling to understand metastatic potential.
- **Clinical Implications**: Patients with metastatic gliomas tend to have shorter survival and more complex treatment pathways. Barthel calls for tailored therapeutic strategies and inclusion of these cases in clinical trials.
- **Diagnostic Challenges**: The article highlights the difficulty in distinguishing true metastases from multifocal disease or treatment-related changes, underscoring the importance of advanced imaging and molecular diagnostics.

🔬 Comparison: ORIEN Glioblastoma Study (2024) – *Profiling the Molecular and Clinical Landscape of Glioblastoma*

This study provides a broader molecular and clinical analysis of glioblastoma cases using the ORIEN dataset. Key contrasts:

Feature	Barthel (2025)	ORIEN Study (2024)
Focus	Metastatic gliomas	Glioblastoma (GBM) overall
Sample Type	Rare metastatic cases	Large cohort under 2021 WHO criteria
Molecular Depth	Editorial overview	Full genomic and transcriptomic profiling
Clinical Insight	Emphasizes rarity and poor prognosis	Stratifies GBM by molecular subtype and outcome
Call to Action	Inclusion in trials, better diagnostics	Reclassification and precision medicine pathways

While Barthel's article is a focused editorial on a rare subset, the ORIEN study offers a comprehensive landscape of GBM, reinforcing the need for molecular stratification in all glioma types.

📚 Bibliography (Vancouver Style)

1. Barthel FP. Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas. Neuro Oncol. 2025 Oct 15:noaf244. doi: 10.1093/neuonc/noaf244. Epub ahead of print. PMID: 41092320. Available from:

2. Barnholtz-Sloan JS, et al. Profiling the molecular and clinical landscape of glioblastoma: ORIEN study. Neurooncol Adv. 2024;6(1):vdae046. doi: 10.1093/noa/vdae046. Available from:

If you'd like, I can help you explore more comparative studies or visualize the molecular differences between glioma subtypes.

Oxford Academic

Uncommon Territory: The Clinical and Molecular Profile of Metastatic ...

Oxford Academic

Profiling the molecular and clinical landscape of glioblastoma ...

> Key findings of the article: "Barthel FP. Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas. Neuro Oncol. 2025 Oct 15:noaf244. doi: 10.1093/neuonc/noaf244. Epub ahead of print. PMID: 41092320." Comparing also with similar articles. At the end give me the intere bibliography you used, in Vancouver form.

Here's a detailed summary of the key findings from Barthel's 2025 article on metastatic gliomas, compared with recent studies on glioblastoma and glioma molecular profiling. I've also included the full bibliography in Vancouver format.

🧠 Key Findings: Barthel FP (2025) – *Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas*

This editorial highlights the rare and poorly understood phenomenon of gliomas that metastasize outside the central nervous system (CNS). Key insights include:

- **Rarity of Extracranial Spread**: Metastatic gliomas are extremely rare, with extracranial metastases occurring in less than 2% of glioma cases.
- **Molecular Complexity**: These tumors often exhibit aggressive molecular features such as TP53 mutations, EGFR amplification, and CDKN2A/B deletions. Barthel emphasizes the need for comprehensive genomic profiling to understand metastatic potential.
- **Diagnostic Challenges**: Differentiating true metastases from multifocal disease or treatment-related changes is difficult. Advanced imaging and molecular diagnostics are essential.
- **Clinical Implications**: Patients with metastatic gliomas typically have worse outcomes and more complex treatment needs. Barthel calls for their inclusion in clinical trials and tailored therapeutic strategies.

🔬 Comparison with Similar Articles

1. *Glioblastoma Multiforme: Insights into Pathogenesis and Therapeutic Strategies* (Pouyan et al., 2025)

- Focuses on glioblastoma multiforme (GBM), the most aggressive primary brain tumor.
- Highlights key molecular drivers: EGFR, PTEN, IDH1/2, and MGMT methylation status.
- Discusses resistance to therapy and poor prognosis (median survival ~15 months).
- Emphasizes the role of tumor heterogeneity and the blood–brain barrier in limiting treatment efficacy.

2. *Molecular Profiling in Targeted Therapy of Gliomas in a Community Setting* (ASCO, 2025)

- Retrospective study of 61 glioma patients using multigene panels.
- Demonstrates the feasibility of molecular profiling in non-academic settings.
- Supports the use of personalized therapy based on genetic alterations.

3. *Molecular Biology of Glioblastoma: What Do We Know?* (Ismailov et al., 2025)

- Reviews the molecular landscape of GBM, including immune evasion and tumor microenvironment.
- Highlights emerging targets for immunotherapy and precision medicine.
- Stresses the need for integrative multi-omics approaches.

📚 Bibliography (Vancouver Style)

1. Barthel FP. Uncommon Territory: The Clinical and Molecular Profile of Metastatic Gliomas. Neuro Oncol. 2025 Oct 15:noaf244. doi: 10.1093/neuonc/noaf244. Epub ahead of print. PMID: 41092320. Available from:

2. Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24:58. doi: 10.1186/s12943-025-02267-0. Available from:

3. Santos M, Restini F, Fagundes S, Moraes F, Marta G, Hanna S, et al. Molecular profiling of gliomas: insights into radionecrosis and pseudoprogression through next-generation sequencing. Neuro Oncol. 2024 Nov;26(Suppl 8):viii77. doi: 10.1093/neuonc/noae165.0307. Available from:

4. Ismailov A, Spallone A, Belogurov A Jr, Herbert A, Poptsova M. Molecular biology of the deadliest cancer – glioblastoma: what do we know? Front Immunol. 2025 Mar 20;16:1530305. doi: 10.3389/fimmu.2025.1530305. Available from:

5. Felistia Y, Wen PY. Molecular Profiling and Targeted Therapies in Gliomas. Curr Neurol Neurosci Rep. 2023 Oct;23:627–636. doi: 10.1007/s11910-023-01299-7. Available from:

6. ASCO. Molecular profiling in targeted therapy of gliomas in a community setting. J Clin Oncol. 2025;43(16_suppl):e14030. doi: 10.1200/JCO.2025.43.16_suppl.e14030. Available from:

Let me know if you'd like a visual comparison chart or a deeper dive into any of these molecular pathways.

Oxford Academic

Uncommon Territory: The Clinical and Molecular Profile of Metastatic ...

Molecular Cancer

Glioblastoma multiforme: insights into pathogenesis, key signaling ...